$1.64 Billion is the total value of Consonance Capital Management LP's 35 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GWPH | New | GW PHARMACEUTICALS PLCads | $63,217,000 | – | 604,604 | +100.0% | 3.86% | – |
| EXAS | New | EXACT SCIENCES CORP | $53,608,000 | – | 579,666 | +100.0% | 3.27% | – |
| AXGN | New | AXOGEN INC | $53,426,000 | – | 2,986,386 | +100.0% | 3.26% | – |
| ASMB | New | ASSEMBLY BIOSCIENCES INC | $38,432,000 | – | 1,878,395 | +100.0% | 2.35% | – |
| ISEE | New | IVERIC BIO INC | $29,398,000 | – | 3,426,365 | +100.0% | 1.79% | – |
| LMNL | New | LIMINAL BIOSCIENCES INC | $27,548,000 | – | 3,287,311 | +100.0% | 1.68% | – |
| New | APTOSE BIOSCIENCES INC | $27,058,000 | – | 4,772,190 | +100.0% | 1.65% | – | |
| OVID | New | OVID THERAPEUTICS INC | $11,989,000 | – | 2,888,888 | +100.0% | 0.73% | – |
| BEAT | New | BIOTELEMETRY INC | $7,177,000 | – | 155,000 | +100.0% | 0.44% | – |
| FOLD | New | AMICUS THERAPEUTICS INC | $4,945,000 | – | 507,739 | +100.0% | 0.30% | – |
| TPTX | New | TURNING POINT THERAPEUTICS I | $4,441,000 | – | 71,300 | +100.0% | 0.27% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $4,134,000 | – | 135,000 | +100.0% | 0.25% | – |
| MOR | New | MORPHOSYS AGsponsored ads | $769,000 | – | 21,561 | +100.0% | 0.05% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP DEL | 29 | Q2 2022 | 15.9% |
| ADMA BIOLOGICS INC | 27 | Q4 2020 | 2.3% |
| RETROPHIN INC | 23 | Q1 2020 | 11.3% |
| ANI PHARMACEUTICALS INC | 23 | Q3 2019 | 7.9% |
| VERICEL CORP | 21 | Q4 2019 | 5.5% |
| AMARIN CORP PLC | 14 | Q3 2019 | 14.4% |
| GLOBUS MED INC | 13 | Q2 2022 | 24.7% |
| ORTHOFIX INTL N V | 13 | Q3 2016 | 9.7% |
| PACIFIC BIOSCIENCES CALIF IN | 13 | Q4 2018 | 9.7% |
| CATALYST PHARM PARTNERS INC | 13 | Q3 2019 | 9.4% |
View Consonance Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Surrozen, Inc./DESold out | December 15, 2022 | 0 | 0.0% |
| ADMA BIOLOGICS, INC. | February 14, 2022 | 1,289,481 | 1.4% |
| ASSEMBLY BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| CASI Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cellectar Biosciences, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Gamida Cell Ltd.Sold out | February 14, 2022 | 0 | 0.0% |
| GenMark Diagnostics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Protagonist Therapeutics, IncSold out | February 14, 2022 | 0 | 0.0% |
| Sio Gene Therapies Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Consonance-HFW Acquisition Corp. | April 27, 2021 | 1,000,000 | 10.4% |
View Consonance Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-12-15 |
| SC 13D/A | 2022-12-15 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Consonance Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.